Evaluation

15 drugs in development·13 companies·2 clinical trials

Drug Pipeline by Phase

Approved(10)

Drug	Company
atomoxetine	Aptinyx Inc. (APTX)
atomoxetine	Teva Pharmaceutical Industries Limited (TEVA)
atomoxetine	DR REDDYS LABORATORIES LTD (RDY)
exforge hct	Novartis AG (NVS)
losartan	Teva Pharmaceutical Industries Limited (TEVA)
nebivolol	ANI PHARMACEUTICALS INC (ANIP)
neuraceq	Lantheus Holdings, Inc. (LNTH)
olmesartan medoxomil	Amneal Pharmaceuticals, Inc. (AMRX)
telmisartan	Inventiva S.A. (IVA)
vizamyl	GE HealthCare Technologies Inc. (GEHC)

Phase 2(3)

Drug	Company
AKB-097	Akebia Therapeutics, Inc. (AKBA)
imvotamab	IGM Biosciences, Inc. (IGMS)
Sapanisertib (CB-228, formerly TAK-228)	Calithera Biosciences, Inc. (CALA)

Phase 1(1)

Drug	Company
AKB-10108	Akebia Therapeutics, Inc. (AKBA)

Preclinical(1)

Drug	Company
HBS-102	Harmony Biosciences Holdings, Inc. (HRMY)

BioSniper tracks 15 drugs in development for Evaluation across 13 companies.

There are 2 clinical trials targeting Evaluation tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.